Advertise on podcast: Journal of Clinical Oncology (JCO) Podcast

Host Dr. Jake New interviews Dr. Alexander Sherry and Dr. Chad Tang about their JCO article, "Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets From the Phase II Randomized EXTEND Trial."  They discuss the significance of histology-specific basket design, and the potential of circulating tumor DNA to guide treatment decisions. LINK TO FULL TRANSCRIPT

What long-term outcomes can be achieved with neoadjuvant cemiplimab, and how does immunotherapy reshape the treatment landscape for advanced cutaneous squamous cell carcinoma? Host Dr. Davide Soldato interviews Dr. Neil Gross on his simultaneous publication presented at ESMO 2026 "A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II–IV Cutaneous Squamous Cell Carcinoma: Final Analysis." They explore the clinical rationale, long-term survival and durability outcomes, and the profound impact of this approach on surgical morbidity and patient quality of life. Dr. Gross also shares insights on how these results are paving the way for ongoing randomized trials and the future of treatment personalization in advanced skin cancers.

What pCR rates can be achieved with neoadjuvant THP, and which patients are most likely to respond? Host Dr. Davide Soldato interviews Dr. Nadine Tung on her article, "Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR." They examine differences in pCR by estrogen receptor status and the clinicopathologic and HER2DX features associated with response, while considering how these findings may inform treatment personalization as the trial's 3-year recurrence-free survival data mature. LINK TO FULL TRANSCRIPT

Host Dr. Jake New interviews Dr. Makoto Tahara about the JCO article "Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer." They discuss clinical considerations for individualizing treatment schedules and impact of treatment schedule on toxicity and patient quality of life. LINK TO FULL TRANSCRIPT

How does dexrazoxane affect left ventricular function over time after doxorubicin treatment for childhood cancer? Host Dr. Davide Soldato sits down with Dr. Erin Mobley and Dr. Eric Chow to discuss their article, "Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report from COG ALTE11C2." They examine the longitudinal echocardiographic findings, the durability of cardioprotection, and how dexrazoxane exposure might eventually inform cardiomyopathy risk stratification and surveillance. LINK TO FULL TRANSCRIPT

Guest Dr. Vedang Murthy and host Davide Soldato discuss JCO article, "Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer" and delve into trial design, results, clinical implications, and future directions in bladder cancer treatment. LINK TO FULL TRANSCRIPT

In this episode of JCO Article Insights, host Ash Gurumurthi summarizes the article "Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma," by Mehta-Shah and colleagues. LINK TO FULL TRANSCRIPT

Guests Dr. Elise Park, Dr. Jamie Ostrov and host Dr. Davide Soldato discuss JCO article "Virtual Sustained Tobacco Treatment for Cancer Patients: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) within the NCI Community Oncology Research Program (NCORP)" and their groundbreaking trial on virtual tobacco cessation treatment for cancer patients in community settings. LINK TO FULL TRANSCRIPT

Guests Akash Kulgod and Dr. Sanjeev Kulgod and host Dr. Davide Soldato discuss JCO article, "Canine Olfaction Combined with Bayesian Modeling for Multi Cancer Detection from Breath Samples, a Phase 2 Study in India" and the innovative breath-based canine olfaction for multi-cancer detection in low-resource settings, the Bayesian modeling integration, and future prospects for scalable, non-invasive cancer screening methods. LINK TO FULL TRANSCRIPT

JCO Editorial Fellow Dr. Ash Gurumurthi and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2026 Simultaneous Publication paper "Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study." LINK TO FULL TRANSCRIPT

JCO Podcast host Dr. Davide Soldato and JCO Associate Editor Dr. Dr. Eileen M. O'Reilly discuss the ASCO 2026 Simultaneous Publication paper "Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial." LINK TO FULL TRANSCRIPT

JCO Editorial Fellow Dr. Yuvanesh Vedaraju and JCO Associate Editor Dr. Kathy Miller discuss the ASCO 2026 Simultaneous Publication paper "Low-Dose Tamoxifen in Non-Invasive Breast Neoplasia: Long-Term Results from an Individual Participant Data Pooled Analysis." LINK TO FULL TRANSCRIPT

JCO Editorial Fellow Dr. Jake New and JCO Associate Editor Dr. Umang Swami discuss the ASCO 2026 Simultaneous Publication paper "Neoadjuvant Sacituzumab Govitecan in Patients with Muscle-Invasive Bladder Cancer: Primary Results of SURE-01 Trial." LINK TO FULL TRANSCRIPT

JCO Editorial Fellow Dr. Jake New and JCO Associate Editor Dr. Andrea Necchi discuss the ASCO 2026 Simultaneous Publication paper "Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single Arm Phase 2 Trial SAKK 06/19." LINK TO FULL TRANSCRIPT

Guest Dr. Glenwood Goss and host Dr. Davide Soldato discuss JCO article, "Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer" and the implications of minimal residual disease,  results regarding the efficacy of immunotherapy in the adjuvant setting, and the evolving strategies for patient care in lung cancer treatment. LINK TO FULL TRANSCRIPT